"Participants in the music group were given a choice from 8 music CDs with various types of music (e.g., classical, harp, general instrumental, nature sounds, country, gospel, and jazz).","Participants music choice 8 music CDs types music (e.g., classical, harp, instrumental, nature sounds, country, gospel, jazz).",C0679646|C0026867|C0008300|G0000000|C0026867|C0079141|C0332307|C0026867|G0000000|C0439858|G0000000|G0000000|C0349590|C0037709|C0454664|C2239886|G0000000
The control Group received only IV fluids and antipyretics whenever it was indicated.,The control Group received IV fluids antipyretics indicated.,G0000000|C0243148|C0441833|C1514756|C0022326|C0302908|C0003419|C1444656
Patients randomized to receive amifostine were given a dose of 740 mg/m2 intravenously over 15 minutes prior to each administration of a platinum agent.,Patients randomized receive amifostine dose 740 mg/m2 intravenously 15 minutes prior administration platinum agent.,C0030705|C0034656|C1514756|C0015020|C0178602|C1442061|C0026410|G0000000|C0450371|C0439232|C0332152|C0001554|C0032207|C0450442
"Of the 77,445 participants randomly assigned to screening (intervention group), 83.5% underwent baseline flexible sigmoidoscopy and 54.0% were screened at 3 or 5 years.","Of 77,445 participants randomly assigned screening (intervention group), 83.5% underwent baseline flexible sigmoidoscopy 54.0% screened 3 5 years.",G0000000|C0450371|C0679646|G0000000|C1516050|C0220908|C0886296|C0441833|C0450371|G0000000|C0168634|C0443220|C0037075|C0450371|C0220908|G0000000|G0000000|C0439234
Cases were assigned randomly to apply treatment and placebo ointments to right or left side lesions (similar location and size).,Cases assigned randomly apply treatment placebo ointments left lesions (similar location size).,C0868928|C1516050|G0000000|C1632850|C0039798|C0032042|C0028912|C0205091|C0221198|C2348205|C0450429|C0456389
"The second intervention (“Introduction of Solids”) taught parents about hunger and satiety cues, the timing for the introduction of solid foods, and how to overcome infants’ initial rejection of healthy foods through repeated exposure.","The intervention (“Introduction Solids”) taught parents hunger satiety cues, timing introduction solid foods, overcome infants’ initial rejection healthy foods repeated exposure.",G0000000|C0886296|G0000000|G0000000|C0348054|C0030551|C0020175|C0036239|C0010439|C0449243|C1293116|C0205208|C0016452|C2983310|G0000000|C0205265|C0035015|C3898900|C0016452|C0205341|C0274281
"The study had two arms: the early exercise group (EEG; n=32) completed the exercise program from baseline to 4 weeks, whereas the delayed exercise group (DEG; n=30) completed the exercise program from 4 to 8 weeks.","The study arms: exercise (EEG; n=32) completed exercise program baseline 4 weeks, delayed exercise (DEG; n=30) completed exercise program 4 8 weeks.",G0000000|C0557651|C0206655|C0015259|C0013819|C0369718|C0205197|C0015259|C1709697|C0168634|G0000000|C0439230|C0205421|C0015259|C2348088|C0369718|C0205197|C0015259|C1709697|G0000000|G0000000|C0439230
They were randomised to drop treatment with chlorhexidine gluconate 0.2% or the standard local treatment natamycin 2.5%.,They randomised drop treatment chlorhexidine gluconate 0.2% standard local treatment natamycin 2.5%.,G0000000|G0000000|C1321095|C0039798|C0008196|C0017714|G0000000|C1442989|C0205276|C0039798|C0027444|G0000000
"Specific aims of this National Cancer Institute-sponsored, 3-armed, randomized controlled trial (RCT) were to explore the feasibility of a mother-daughter weight loss intervention and evaluate whether an individual approach in which mothers and daughters work in parallel to achieve diet and exercise goals or a team-based approach in which mother-daughter dyads work as a team to achieve these goals yielded greater reductions in body mass index (BMI) from baseline to 12-month follow-up.","Specific aims National Cancer Institute-sponsored, 3-armed, randomized controlled trial (RCT) explore feasibility mother-daughter weight loss intervention evaluate individual approach mothers daughters parallel achieve diet exercise goals team-based approach mother-daughter dyads team achieve goals yielded reductions body mass (BMI) baseline 12-month follow-up.",C0205369|C1947946|C3245503|C0006826|C0021622|C0446516|C0034656|C2587213|C0008976|G0000000|G0000000|G0000000|C0026591|C0005910|C1517945|C0886296|C0220825|C0027361|C0449445|C0026591|C0011011|C2348042|G0000000|C0012155|C0015259|C0018017|C0871489|C0449445|C0026591|C0870454|C0871489|G0000000|C0018017|G0000000|C0301630|C0242821|C0577559|G0000000|C0168634|C0450371|C0589120
"Patients with PAH (idiopathic [IPAH] or associated with connective tissue disease [APAH-CTD]) taking bosentan (62.5 or 125 mg twice daily at a stable dose for ≥3 months) were randomized (1:1) to sildenafil (20 mg, 3 times daily; n = 50) or placebo (n = 53).","Patients PAH (idiopathic [IPAH] connective tissue disease [APAH-CTD]) bosentan (62.5 125 daily stable dose ≥3 months) randomized (1:1) sildenafil (20 mg, 3 times daily; = 50) placebo (n = 53).",C0030705|C3203102|C0332240|C0152171|G0000000|C0040300|C0012634|C0245778|C0252643|C0450371|C1442061|C0332173|C0205360|C0178602|G0000000|C0439231|C0034656|G0000000|C0529793|C0450371|C0026410|G0000000|C0040223|C0332173|G0000000|C0450371|C0032042|C0369718|G0000000|C0450371
"Intervention group received olanzapine tablets manufactured in Dr. Abidi Pharmaceutical Company, Tehran, Iran (2.5 mg/day up to maximum dose of 10 mg/day, based on the patient tolerance),[14] a day prior to the beginning of chemotherapy; in the 1st day of chemotherapy to 8 weeks after chemotherapy, besides the routine treatment regimens.","Intervention received olanzapine tablets manufactured Dr. Abidi Pharmaceutical Company, Tehran, Iran (2.5 mg/day maximum dose 10 mg/day, based patient tolerance),[14] day prior chemotherapy; 1st day chemotherapy 8 weeks chemotherapy, routine treatment regimens.",C0886296|C1514756|C0171023|C0039225|C0870840|C0013014|G0000000|C0031336|C0683757|G0000000|C0022065|G0000000|C0439422|C0806909|C0178602|C0450371|C0439422|C1527178|C0030705|C0013220|C0332173|C0332152|C0013216|G0000000|C0332173|C0013216|G0000000|C0439230|C0013216|C0205547|C0039798|C2945654
A total of 109 children were randomly assigned to receive cisplatin plus sodium thiosulfate (57 children) or cisplatin alone (52) and could be evaluated.,A total 109 children randomly assigned receive cisplatin sodium thiosulfate (57 children) cisplatin (52) evaluated.,G0000000|C0439175|C1442061|C0008059|G0000000|C1516050|C1514756|C0008838|C0037473|C0039950|C0450371|C0008059|C0008838|C0450371|C0220825
"Subjects were randomized to the enhanced intervention (n=195), minimal intervention (n= 199) or control (n=198) groups.","Subjects randomized enhanced intervention (n=195), minimal intervention (n= 199) control (n=198) groups.",C0681850|C0034656|C2349975|C0886296|C0369718|C0547040|C0886296|C0369718|C1442061|C0243148|C0369718|C0441833
"Among patients randomized to the intervention study arm, a nephrologist or transplant surgeon will use iChoose Kidney to provide individualized risk estimates of mortality or survival by treatment (dialysis vs. transplant; LD vs. DD transplant) based on a patient’s demographic and clinical characteristics.","Among patients randomized intervention study arm, nephrologist transplant surgeon iChoose Kidney provide individualized risk estimates mortality survival treatment (dialysis vs. transplant; LD vs. DD transplant) based patient’s demographic clinical characteristics.",G0000000|C0030705|C0034656|C0886296|C0557651|C0446516|C0260039|C0040732|C0582175|G0000000|C0022646|C1999230|C1881197|C0035647|C0750572|C0026565|C0038952|C0039798|C0011945|G0000000|C0040732|C0694649|G0000000|C3538867|C0040732|C1527178|G0000000|C0011298|C0205210|C1521970
Hundred patients undergoing elective small bowel anastomosis for the closure of stoma were randomly assigned to the study group (n=50) and the control group (n=50).,Hundred patients undergoing elective bowel anastomosis closure stoma randomly assigned study (n=50) control (n=50).,G0000000|C0030705|G0000000|C0206058|C0021853|C0332853|C0185003|C1955856|G0000000|C1516050|C0557651|C0369718|C0243148|C0369718
"In that trial, a nutrition, stimulation and hygiene education was delivered to mothers in the intervention group while the control group received routine health care.","In trial, nutrition, stimulation hygiene education delivered mothers intervention control received routine health care.",G0000000|C0008976|C0028707|C1292856|C0020405|C0013621|C1705822|C0026591|C0886296|C0243148|C1514756|C0205547|C0018684|C1947933
"Participants were randomly assigned to receive either the control, (based on an NHS Cervical Screening Programme leaflet currently used), or the intervention leaflet (containing additional information on risks and uncertainties).","Participants randomly assigned receive control, (based NHS Cervical Screening Programme leaflet used), intervention leaflet (containing additional risks uncertainties).",C0679646|G0000000|C1516050|C1514756|C0243148|C1527178|C0796085|C0027530|C0220908|C1709697|C1708664|C1273517|C0886296|C1708664|C0332256|C1524062|C0035647|C0087130
"For subjects in the transfusion arm, daily transfusions were continued for up to 42 days but were discontinued if 1 or more of the following occurred: (1) neutrophil recovery, (2) resolution or improvement of the underlying infection (at the discretion of the patient’s physician) provided the subject received at least 5 granulocyte transfusions over at least a 7-day period, or (3) life-threatening toxicity.","For subjects transfusion arm, daily transfusions continued 42 days discontinued 1 occurred: (1) neutrophil recovery, (2) resolution improvement underlying infection (at discretion patient’s physician) provided subject received 5 granulocyte transfusions 7-day period, (3) life-threatening toxicity.",G0000000|C0681850|C0005841|C0446516|C0332173|C0005841|C0549178|C0450371|C0439228|C1444662|G0000000|C1709305|G0000000|C0027950|C0237820|G0000000|C1514893|C2986411|G0000000|C0009450|G0000000|G0000000|G0000000|C0031831|C1999230|C0681850|C1514756|G0000000|C0018183|C0005841|C0332173|C0439531|G0000000|C1517874|C0040539
"Participants were randomly assigned into one of three groups: 1) control (N=59), 2) Oncologists’ exercise recommendation (N=53), and 3) Oncologists’ exercise recommendation with exercise motivation package (N=50).","Participants randomly assigned groups: 1) control (N=59), 2) Oncologists’ exercise recommendation (N=53), 3) Oncologists’ exercise recommendation exercise motivation package (N=50).",C0679646|G0000000|C1516050|C0441833|G0000000|C0243148|C0369718|G0000000|G0000000|C0015259|C0034866|C0369718|G0000000|G0000000|C0015259|C0034866|C0015259|C0026605|C0013194|C0369718
"One hundred forty-nine volunteers 5 to 17 years old (mean [SD] age, 9.4 [3.1] years) were randomized to receive citalopram (n = 73) or placebo (n = 76).","One forty-nine volunteers 5 17 (mean [SD] age, 9.4 [3.1] years) randomized receive citalopram (n = 73) placebo (n = 76).",C0205447|C3816450|C0042960|G0000000|C0450371|C0444504|C2699239|C0001779|G0000000|G0000000|C0439234|C0034656|C1514756|C0008845|C0369718|G0000000|C0450371|C0032042|C0369718|G0000000|C0450371
"Eligible patients were equally randomized to one of the four following treatment arms in a double-blinded manner: GTE (500 mg/m2), GTE (750 mg/m2), GTE (1000 mg/m2), or placebo.","Eligible patients equally randomized treatment arms double-blinded manner: GTE (500 mg/m2), GTE (750 mg/m2), GTE (1000 mg/m2), placebo.",C1548635|C0030705|G0000000|C0034656|C0039798|C0206655|C0205173|G0000000|G0000000|C1442061|C0026410|G0000000|C1442061|C0026410|G0000000|G0000000|C0026410|C0032042
"For patients randomly assigned to the goserelin group, goserelin at a dose of 3.6 mg was administered subcutaneously every 4 weeks beginning 1 week before the initial chemotherapy dose and was continued to within 2 weeks before or after the final chemotherapy dose.","For patients randomly assigned goserelin group, goserelin dose 3.6 administered subcutaneously 4 weeks 1 week initial chemotherapy dose continued 2 weeks final chemotherapy dose.",G0000000|C0030705|G0000000|C1516050|C0120107|C0441833|C0120107|C0178602|G0000000|C1521801|G0000000|G0000000|C0439230|G0000000|C0332174|C0205265|C0013216|C0178602|C0549178|G0000000|C0439230|C0205088|C0013216|C0178602
"In a pragmatic, cluster-randomized, multiple-crossover trial conducted in five intensive care units at an academic center, we assigned 15,802 adults to receive saline (0.9% sodium chloride) or balanced crystalloids (lactated Ringer’s solution or Plasma-Lyte A) according to the randomization of the unit to which they were admitted.","In pragmatic, cluster-randomized, multiple-crossover trial conducted intensive care units academic center, assigned 15,802 adults receive saline (0.9% sodium chloride) balanced crystalloids (lactated Ringer’s solution Plasma-Lyte A) randomization unit admitted.",G0000000|C0871858|C1555715|C0439064|C0008976|C0004927|C0162425|C1947933|C0439148|C1510747|C0205099|C1516050|C0450371|C0001675|C1514756|C0036082|G0000000|C0037473|C0008203|C0205415|C0056562|C0022924|G0000000|C0037633|C0071208|G0000000|C0034656|C0439148|C0184666
"The intervention includes 3 hours + 30 minutes per week of supervised and structured aerobic training (moderate to high intensity 70 - 80%) on an ergometer cycle, strength exercises using hand weights and relaxation exercise.","The intervention includes 3 hours + 30 minutes week supervised structured aerobic training (moderate intensity 70 - 80%) ergometer cycle, strength exercises hand weights relaxation exercise.",G0000000|C0886296|C0332257|G0000000|G0000000|C0439232|C0332174|G0000000|C0678594|C1510824|C0040607|C0205081|C0522510|C0450371|G0000000|C0450371|C0180748|C1511572|C0237897|C0015259|C0018563|C0043100|C0035028|C0015259
"They were then assigned randomly, within those strata and in balanced blocks of four children, to undergo insertion of tympanostomy tubes either promptly (the early-treatment group) or six months later if bilateral effusion persisted or nine months later if unilateral effusion persisted (the delayed-treatment group).","They assigned randomly, strata balanced blocks children, undergo insertion tympanostomy tubes (the early-treatment group) months bilateral effusion persisted months unilateral effusion persisted (the delayed-treatment group).",G0000000|C1516050|G0000000|G0000000|C0205415|C0028778|C0008059|G0000000|C0021107|C0087123|C0175730|G0000000|C1279919|C0441833|C0439231|C0238767|C0013687|G0000000|C0439231|C0205092|C0013687|G0000000|G0000000|C0205421|C0441833
The objective of this study was to evaluate the effect of a psychological attachment‐oriented couple intervention for breast cancer patients and partners in the early treatment phase.,The objective study evaluate psychological attachment‐oriented couple intervention breast cancer patients partners treatment phase.,G0000000|C0018017|C0557651|C0220825|C0205486|G0000000|C0010222|C0886296|C0006141|C0006826|C0030705|C0682323|C0039798|C0205390
"Seven patients were assigned as a block as follows: 2 to a group given the pH-dependent release formulation at 2.4 g/day (pH-2.4 g), 2 to a group given the pH-dependent release formulation at 3.6 g/day (pH-3.6 g), 2 to a group given the time-dependent release formulation at 2.25 g/day (Time-2.25 g), and 1 to a group given placebo (Placebo).","Seven patients assigned block follows: 2 pH-dependent release formulation 2.4 g/day (pH-2.4 g), 2 pH-dependent release formulation 3.6 g/day (pH-3.6 g), 2 time-dependent release formulation 2.25 g/day (Time-2.25 g), 1 placebo (Placebo).",C0205453|C0030705|C1516050|C0028778|C0332283|G0000000|C0450407|C0030685|C0524527|G0000000|C0439417|C0450407|C0439267|G0000000|C0450407|C0030685|C0524527|G0000000|C0439417|C0450407|C0439267|G0000000|C0040223|C0030685|C0524527|C0450371|C0439417|C0040223|C0439267|G0000000|C0032042|C0032042
"Sixty-three post-treatment stage 0–III borderline overweight and obese (body mass index ≥ 24 kg/m2) breast cancer survivors were randomly assigned to a 6-month, facility- and home-based viniyoga intervention (n = 32) or a waitlist control group (n = 31).","Sixty-three post-treatment stage 0–III borderline overweight obese (body mass ≥ 24 kg/m2) breast cancer survivors randomly assigned 6-month, facility- home-based viniyoga intervention (n = 32) waitlist control (n = 31).",C3816724|C2709088|C0205390|G0000000|C0205189|C0497406|C0028754|C0242821|C0577559|G0000000|C0450371|C0022718|C0006141|C0006826|C0206194|G0000000|C1516050|C0332177|C1547538|C0442519|G0000000|C0886296|C0369718|G0000000|C0450371|C0043010|C0243148|C0369718|G0000000|C0450371
Participants will receive either standard specialist-based follow-up care (usual follow-up care) or shared follow-up care between specialist and PCP (shared care intervention) for a period of 12 months.,Participants receive standard specialist-based follow-up care (usual follow-up care) shared follow-up care specialist PCP (shared care intervention) period 12 months.,C0679646|C1514756|C1442989|C0087009|C0589120|C1947933|C3538928|C0589120|C1947933|C0237876|C0589120|C1947933|C0087009|C1535939|C0237876|C1947933|C0886296|C0439531|C0450371|C0439231
Infants were then randomized to either continue NIMV or NIV-NAVA for 3 h after nursing care and then crossed over to the alternate mode until after the next nursing care.,Infants randomized continue NIMV NIV-NAVA 3 h nursing care crossed alternate mode nursing care.,C0021270|C0034656|C0549178|G0000000|C0598902|G0000000|C0006147|C1947933|C0205203|C0332270|C1513371|C0006147|C1947933
"Children were allocated to groups using minimisation randomization (balanced 1:1 for age, CC2 nonword reading, CC2 irregular word reading; executed using MINIMPY; Saghaei, 2011), which is considered the most appropriate sequence allocation procedure for trials comprising fewer than 100 participants.","Children allocated minimisation randomization (balanced 1:1 age, CC2 nonword reading, CC2 irregular word reading; executed MINIMPY; Saghaei, 2011), considered sequence allocation procedure trials comprising fewer 100 participants.",C0008059|G0000000|G0000000|C0034656|C0205415|G0000000|C0001779|C0055717|G0000000|C0034754|C0055717|C0205271|C1705313|C0034754|C1705848|G0000000|G0000000|G0000000|C0750591|C0004793|C1706778|C0184661|C0008976|C2700400|C0205388|C1442061|C0679646
Patients then received either the hypnosis intervention or remained on a no-treatment waiting list for 5 weeks.,Patients received hypnosis intervention remained no-treatment waiting list 5 weeks.,C0030705|C1514756|C0020587|C0886296|G0000000|C0039798|C1610166|C0745732|G0000000|C0439230
Patients on Arm 1 received the first dose of zoledronic acid concurrently with the start of RT and then every six months for a total of 3 years (6 infusions).,Patients Arm 1 received dose zoledronic acid concurrently start RT months total 3 (6 infusions).,C0030705|C0446516|G0000000|C1514756|C0178602|C1177229|C0001128|G0000000|C0439659|C0230425|C0439231|C0439175|G0000000|G0000000|C0574032
"Inc-AA infants received 1.7 g/kg amino acids on day 1, 2.1 g/kg on day 2, and a maximum of 2.7 g · kg−1 · d−1 from day 3; Imm-RDI infants received 3.6 g · kg−1 · d−1 from day 1.","Inc-AA infants received 1.7 g/kg amino acids day 1, 2.1 g/kg day 2, maximum 2.7 · kg−1 · d−1 day 3; Imm-RDI infants received 3.6 · kg−1 · d−1 day 1.",C0282379|C0021270|C1514756|G0000000|C1300563|G0000000|C0001128|C0332173|G0000000|G0000000|C1300563|C0332173|G0000000|C0806909|G0000000|G0000000|G0000000|G0000000|G0000000|C0332173|G0000000|C0205470|C0021270|C1514756|G0000000|G0000000|G0000000|G0000000|G0000000|C0332173|G0000000
Patients were randomly assigned with equal probability to receive either bevacizumab (10 mg/kg given intravenously every 2 weeks) plus IFN (9 million U [MU] subcutaneously three times weekly) or the same dose and schedule of IFN as monotherapy.,Patients randomly assigned equal probability receive bevacizumab (10 mg/kg intravenously 2 weeks) IFN (9 U [MU] subcutaneously times weekly) dose schedule IFN monotherapy.,C0030705|G0000000|C1516050|C0205163|C0033204|C1514756|C0796392|C0450371|C0439272|G0000000|G0000000|C0439230|G0000000|G0000000|G0000000|C0028971|G0000000|C0040223|C0332174|C0178602|C0086960|G0000000|G0000000
"Participants were randomly assigned 1:1 to either HPV quadrivalent (types 6, 11, 16, and 18) vaccine (Merck and Co. Inc., Kenilworth, New Jersey) or matched placebo at baseline, week 8, and week 24.","Participants randomly assigned 1:1 HPV quadrivalent (types 6, 11, 16, 18) vaccine (Merck Co. Inc., Kenilworth, New Jersey) matched placebo baseline, week 8, week 24.",C0679646|G0000000|C1516050|G0000000|C0021344|G0000000|C0332307|G0000000|C0450371|C0450371|C0450371|C0042210|G0000000|C3245499|G0000000|G0000000|C0205314|C0454673|C0150103|C0032042|C0168634|C0332174|G0000000|C0332174|C0450371
"Eligible subjects were randomly assigned to double-blind treatment with either gabapentin (1200 mg/day) or placebo, in a 1 : 1 ratio, on the basis of a computer-generated randomization code.","Eligible subjects randomly assigned double-blind treatment gabapentin (1200 mg/day) placebo, 1 : 1 ratio, basis computer-generated randomization code.",C1548635|C0681850|G0000000|C1516050|C0013072|C0039798|C0060926|G0000000|C0032042|G0000000|C0456603|C1527178|C0009622|C0034656|C0009219
Patients randomised to the dietary and exercise intervention will be given individualised healthy eating dietary advice and written information: 'Weight Loss On A Plate' (Scottish Dietetic Association).,Patients randomised dietary exercise intervention individualised healthy eating dietary advice written information: 'Weight Loss On A Plate' (Scottish Dietetic Association).,C0030705|G0000000|C0012155|C0015259|C0886296|G0000000|C3898900|C0013470|C0012155|C0150600|C0043266|C1533716|C0005910|C1517945|G0000000|G0000000|C0005971|C0240966|C0012180|C0004083
"In FOLFIRI alone group, patients were given FOLFIRI only (180 mg/m2 irinotecan, 400 mg/m2 racemic leucovorin by intravenous [IV] infusion on day 1 and FU 400 mg/m2 intravenous bolus on day 1, followed by 2,400 mg/m2 continuous infusion over days 1 and 2), every 2 weeks.","In FOLFIRI group, patients FOLFIRI (180 mg/m2 irinotecan, 400 mg/m2 racemic leucovorin intravenous [IV] infusion day 1 FU 400 mg/m2 intravenous bolus day 1, 2,400 mg/m2 continuous infusion days 1 2), 2 weeks.",G0000000|C1880658|C0441833|C0030705|C1880658|C1442061|C0026410|C0123931|C1442061|C0026410|C3641126|C0023413|C0348016|C0022326|C0574032|C0332173|G0000000|C0016360|C1442061|C0026410|C0348016|C1511237|C0332173|G0000000|C1442061|C0026410|C0549178|C0574032|C0439228|G0000000|G0000000|G0000000|C0439230
"Design: Thirty-five pediatric fellows in cardiology, critical care, hematology/oncology, and neonatology at two institutions enrolled: 17 in the intervention (simulation-based) group (single institution) and 18 in the control (didactic education) group (second institution).","Design: Thirty-five pediatric fellows cardiology, critical care, hematology/oncology, neonatology institutions enrolled: 17 intervention (simulation-based) (single institution) 18 control (didactic education) (second institution).",C1707689|C3816446|C0030755|G0000000|C0007189|C1511545|C1947933|C1441600|C0027621|C1272753|G0000000|C0450371|C0886296|C0679083|C0037179|C0018704|C0450371|C0243148|G0000000|C0013621|C0205436|C0018704
"The comparison group received printed materials (but no counseling) promoting the five-a-day guidelines of daily intakes of five servings of fruit and vegetables, more than 20 g of fiber, and less than 30% of energy intake from fat.","The comparison received printed materials (but counseling) promoting five-a-day guidelines daily intakes servings fruit vegetables, 20 fiber, 30% energy intake fat.",G0000000|C1707455|C1514756|C0033161|C0520510|G0000000|C0010210|C0033414|C0205451|C0162791|C0332173|C1512806|C1519269|C0016767|C0042440|C0450371|C0012173|C0450371|C0424589|C1512806|C0424612
"We prospectively studied 51 children, five to twelve years of age, with femoral fractures treated with either EIN (n = 26) or DSTSC (n = 25).","We prospectively studied 51 children, twelve age, femoral fractures treated EIN (n = 26) DSTSC (n = 25).",G0000000|G0000000|C0557651|C0450371|C0008059|C0205458|C0001779|C0015811|C0016658|C1522326|C1333394|G0000000|G0000000|G0000000
"In total, 132 severely fatigued breast cancer survivors will be recruited and randomized to either an intervention condition or care as usual (ratio 1:1).","In total, 132 severely fatigued breast cancer survivors recruited randomized intervention condition care usual (ratio 1:1).",G0000000|C0439175|C1442061|C0205082|C0015672|C0006141|C0006826|C0206194|G0000000|C0034656|C0886296|C0012634|C1947933|C3538928|C0456603|G0000000
"We randomly assigned 945 previously untreated patients with unresectable stage III or IV melanoma, in 1:1:1 ratio, to nivolumab alone (3 mg per kilogram of body weight every 2 weeks), or to nivolumab (at a dose of 1 mg per kilogram) plus ipilimumab (at a dose of 3 mg per kilogram) every 3 weeks for 4 doses followed by nivolumab (3 mg per kilogram every 2 weeks), or to ipilimumab alone (3 mg per kilogram every 3 weeks for 4 doses).","We randomly assigned 945 untreated patients unresectable stage III IV melanoma, 1:1:1 ratio, nivolumab (3 kilogram body weight 2 weeks), nivolumab (at dose 1 kilogram) ipilimumab (at dose 3 kilogram) 3 weeks 4 doses nivolumab (3 kilogram 2 weeks), ipilimumab (3 kilogram 3 weeks 4 doses).",G0000000|G0000000|C1516050|C1442061|C0332155|C0030705|C1519810|C0205390|C0439070|C0022326|C0025202|G0000000|C0456603|C3657270|G0000000|C0439209|C0242821|C0005910|G0000000|C0439230|C3657270|G0000000|C0178602|G0000000|C0439209|C1367202|G0000000|C0178602|G0000000|C0439209|G0000000|C0439230|G0000000|C0178602|C3657270|G0000000|C0439209|G0000000|C0439230|C1367202|G0000000|C0439209|G0000000|C0439230|G0000000|C0178602
"In this double-blind study, 142 treatment-naïve patients with metastatic melanoma were randomized 2:1 to receive ipilimumab 3 mg/kg combined with either nivolumab 1 mg/kg or placebo every 3 weeks for 4 doses, followed by nivolumab 3 mg/kg or placebo every 2 weeks until disease progression.","In double-blind study, 142 treatment-naïve patients metastatic melanoma randomized 2:1 receive ipilimumab 3 mg/kg combined nivolumab 1 mg/kg placebo 3 weeks 4 doses, nivolumab 3 mg/kg placebo 2 weeks disease progression.",G0000000|C0013072|C0557651|C1442061|G0000000|C0030705|C0036525|C0025202|C0034656|G0000000|C1514756|C1367202|G0000000|C0439272|C0205195|C3657270|G0000000|C0439272|C0032042|G0000000|C0439230|G0000000|C0178602|C3657270|G0000000|C0439272|C0032042|G0000000|C0439230|C0012634|C0242656
This study was designed to compare the proportion of complete responders to weekly methotrexate 30 mg/m2 IM and biweekly dactinomycin 1.25 mg/m2 intravenously.,This study designed compare proportion complete responders weekly methotrexate 30 mg/m2 IM biweekly dactinomycin 1.25 mg/m2 intravenously.,G0000000|C0557651|C1707689|C1707455|C1709707|C0205197|G0000000|C0332174|C0025677|C0450371|C0026410|C3539078|C0585332|C0010934|C0450371|C0026410|G0000000
We randomly assigned patients with newly diagnosed incurable lung or noncolorectal GI cancer to receive either early integrated PC and oncology care (n = 175) or usual care (n = 175) between May 2011 and July 2015.,We randomly assigned patients newly diagnosed incurable lung noncolorectal GI cancer receive integrated PC oncology care (n = 175) usual care (n = 175) May 2011 July 2015.,G0000000|G0000000|C1516050|C0030705|C0750546|C0011900|G0000000|C0024109|G0000000|C1708130|C0006826|C1514756|G0000000|C0031995|C0027651|C1947933|C0369718|G0000000|C1442061|C3538928|C1947933|C0369718|G0000000|C1442061|G0000000|G0000000|C3829447|G0000000
Untreated advanced gastric cancer patients randomly received docetaxel and cisplatin at 60 mg/m2 (day 1) followed by fluorouracil at 600 mg/m2/day (days 1–5; mDCF regimen) or cisplatin at 75 mg/m2 (day 1) followed by fluorouracil at 600 mg/m2/day (days 1–5; CF) every 3 weeks.,Untreated advanced gastric cancer patients randomly received docetaxel cisplatin 60 mg/m2 (day 1) fluorouracil 600 mg/m2/day (days 1–5; mDCF regimen) cisplatin 75 mg/m2 (day 1) fluorouracil 600 mg/m2/day (days 1–5; CF) 3 weeks.,C0332155|C0205179|C0038351|C0006826|C0030705|G0000000|C1514756|C0246415|C0008838|C0450371|C0026410|C0332173|G0000000|C0016360|C1442061|C0439422|C0439228|G0000000|G0000000|C0040808|C0008838|C0450371|C0026410|C0332173|G0000000|C0016360|C1442061|C0439422|C0439228|G0000000|C0009738|G0000000|C0439230
"Four hundred and ninety patients who underwent adjuvant postoperative radiation therapy after surgery for sigmoid, rectal, or cervical cancer were assigned to either the high-potency probiotic preparation VSL#3 (one sachet t.i.d.,) or placebo starting from the first day of radiation therapy.","Four patients underwent adjuvant postoperative radiation therapy surgery sigmoid, rectal, cervical cancer assigned high-potency probiotic preparation VSL#3 (one sachet t.i.d.,) placebo starting day radiation therapy.",C0205450|C0030705|G0000000|C0001551|C0032790|C0034519|C0039798|C0038894|C0227391|C0205052|C0027530|C0006826|C1516050|C0205250|C0525033|C1521827|G0000000|C0205447|C1319685|C2603360|C0032042|C0439659|C0332173|C0034519|C0039798
"In the tacrolimus arm, children received tacrolimus, 0.2 mg/kg/d, targeting trough levels of 5 to 7 ng/mL along with tapering doses of alternate-day prednisolone.","In tacrolimus arm, children received tacrolimus, 0.2 mg/kg/d, targeting trough levels 5 7 ng/mL tapering doses alternate-day prednisolone.",G0000000|C0085149|C0446516|C0008059|C1514756|C0085149|G0000000|C3665414|C1521840|C0444506|C0441889|G0000000|G0000000|C0439275|C0441640|C0178602|C0558287|C0032950
"Overall, both groups received a similar number of treatment cycles (median (range): 5 (1 to 21) with DI, 6 (1 to 14) with DF).","Overall, received treatment cycles (median (range): 5 (1 21) DI, 6 (1 14) DF).",C0282416|C1514756|C0039798|C1511572|C0549183|C1514721|G0000000|G0000000|C0450371|C3538902|G0000000|G0000000|C0450371|G0000000
"Participants randomized to receive the weight loss intervention participated in a 15-week, in-person, group-based program that was led by a health coach with a background in nutrition and an exercise physiologist.","Participants randomized receive weight loss intervention participated 15-week, in-person, group-based program led health coach background nutrition exercise physiologist.",C0679646|C0034656|C1514756|C0005910|C1517945|C0886296|G0000000|C0450371|C1547564|C0441833|C1709697|C1708698|C0018684|C0557773|C1706907|C0028707|C0015259|C0260141
"Interventions Patients randomly allocated to tranexamic acid (loading dose 1 g over 10 minutes, then infusion of 1 g over 8 hours) or matching placebo.","Interventions Patients randomly allocated tranexamic acid (loading dose 1 10 minutes, infusion 1 8 hours) matching placebo.",C0886296|C0030705|G0000000|G0000000|G0000000|C0001128|C1708715|C0178602|G0000000|C0450371|C0439232|C0574032|G0000000|G0000000|C0439227|C0150103|C0032042
"The remaining 146 patients (57 women, 89 men) were randomized in two groups: ES (n = 72) and UC (n = 74).","The remaining 146 patients (57 women, 89 men) randomized groups: ES (n = 72) UC (n = 74).",G0000000|C1527428|C1442061|C0030705|C0450371|C0043210|C0450371|C0025266|C0034656|C0441833|C0013754|C0369718|G0000000|C0450371|G0000000|C0369718|G0000000|C0450371
"Patients were randomised to receive either oral capecitabine (1250 mg m−2 twice daily for 14 days followed by a 7-day rest period) or 5-FU/LV administered according to the Mayo Clinic regimen (LV 20 mg m−2 followed by 5-FU 425 mg m−2, administered as an i.v.","Patients randomised receive oral capecitabine (1250 mg m−2 daily 14 days 7-day rest period) 5-FU/LV administered Mayo Clinic regimen (LV 20 mg m−2 5-FU 425 mg m−2, administered i.v.",C0030705|G0000000|C1514756|C0442027|C0671970|G0000000|C0332173|C0450371|C0439228|C0332173|C0035253|C0439531|C1880814|C1521801|C0454788|C0002424|C0040808|C0023128|G0000000|C0016360|G0000000|C1521801|C0021966
"H groups refers to escalated gefitinib (500 mg/d), while S group refers to standard dose gefitinib (250 mg/d).","H refers escalated gefitinib (500 mg/d), S refers standard dose gefitinib (250 mg/d).",C0033727|C0205543|G0000000|C1122962|G0000000|C0565930|C0205543|C1442989|C0178602|C1122962|G0000000
Patients (within oncologists) will be randomized to either receive the communication aid or care as usual.,Patients (within oncologists) randomized receive communication aid care usual.,C0030705|G0000000|C0259990|C0034656|C1514756|C0009452|C0449435|C1947933|C3538928
"After providing written informed consent, patients were randomly assigned, in a 1:1 ratio, to receive a high-dose bolus of interleukin-2 alone every 8 hours (Proleukin, Prometheus; provided through the patients’ health plans), or gp100:209–217(210M) plus Montanide ISA-51 (provided by the CTEP), given once per cycle, and the same high-dose interleukin-2 regimen beginning the second day of the cycle.","After providing written informed consent, patients randomly assigned, 1:1 ratio, receive high-dose bolus interleukin-2 8 hours (Proleukin, Prometheus; provided patients’ health plans), gp100:209–217(210M) Montanide ISA-51 (provided CTEP), cycle, high-dose interleukin-2 regimen day cycle.",G0000000|C1999230|C0043266|C1522154|C1511481|C0030705|G0000000|C1516050|G0000000|C0456603|C1514756|C0444956|C1511237|C0021764|G0000000|C0439227|C0701339|G0000000|C1999230|G0000000|C0018684|C0270724|G0000000|G0000000|C2805416|C1999230|C1516234|C1511572|C0444956|C0021764|C0040808|C0332173|C1511572
"Patients were randomised to receive either docetaxel 60 mg m−2 (1-h IV infusion, Day 1) followed by irinotecan 250 mg m−2 (30- to 90-min IV infusion, Day 1) every 3 weeks (DI), or docetaxel 85 mg m−2 (1-h IV infusion, day 1) followed by 5-FU 750 mg m−2 per day (continuous infusion, days 1 to 5) every 3 weeks (DF) until disease progression, unacceptable toxicity or withdrawal of consent.","Patients randomised receive docetaxel 60 mg m−2 (1-h IV infusion, Day 1) irinotecan 250 mg m−2 (30- 90-min IV infusion, Day 1) 3 weeks (DI), docetaxel 85 mg m−2 (1-h IV infusion, day 1) 5-FU 750 mg m−2 day (continuous infusion, days 1 5) 3 weeks (DF) disease progression, unacceptable toxicity withdrawal consent.",C0030705|G0000000|C1514756|C0246415|G0000000|C0033727|C0022326|C0574032|C0332173|G0000000|C0123931|G0000000|C0450371|C0450371|C0022326|C0574032|C0332173|G0000000|G0000000|C0439230|C3538902|C0246415|G0000000|C0033727|C0022326|C0574032|C0332173|G0000000|C0016360|G0000000|C0332173|C0549178|C0574032|C0439228|G0000000|G0000000|G0000000|C0439230|G0000000|C0012634|C0242656|C1883420|C0040539|C2349954|C1511481
"Twenty-one adult patients were randomised to receive ghrelin on days 1 and 8 and placebo on days 4 and 11 or vice versa, given intravenously over a 60-min period before lunch: 10 received 2 μg kg−1 (lower-dose) ghrelin; 11 received 8 μg kg−1 (upper-dose) ghrelin.","Twenty-one adult patients randomised receive ghrelin days 1 8 placebo days 4 11 vice versa, intravenously 60-min period lunch: 10 received 2 μg kg−1 (lower-dose) ghrelin; 11 received 8 μg kg−1 (upper-dose) ghrelin.",C3715213|C0001675|C0030705|G0000000|C1514756|C0911014|C0439228|G0000000|G0000000|C0032042|C0439228|G0000000|C0450371|C0814670|G0000000|G0000000|C0450371|C0439531|C2697949|C0450371|C1514756|G0000000|C0445550|C0911014|C0450371|C1514756|G0000000|C1282910|C0911014
"Methods: A randomised clinical trial was performed using 2% econazole or 5% natamycin as the two treatment arms on patients presenting with culture positive fungal keratitis to the cornea service at Aravind Eye Care System, Madurai, India.","Methods: A randomised clinical trial performed 2% econazole 5% natamycin treatment arms patients culture positive fungal keratitis cornea service Aravind Eye Care System, Madurai, India.",C0025663|G0000000|G0000000|C0205210|C0008976|C0884358|G0000000|C0013547|G0000000|C0027444|C0039798|C0206655|C0030705|C0010453|C0439178|C0016832|C0022568|C0010031|C0557854|G0000000|C0015392|C1947933|C0449913|G0000000|C0021201
Children in the comparison group received no intervention in the second session and were not required to spend time at the study site.,Children comparison received intervention session required spend time study site.,C0008059|C1707455|C1514756|C0886296|C1883016|C1514873|C0680968|C0040223|C0557651|C0205145
Single oral dose of 10 mg of dexamethasone (n = 293) or identical placebo (n = 283).,Single oral dose 10 dexamethasone (n = 293) identical placebo (n = 283).,C0037179|C0442027|C0178602|C0450371|C0011777|G0000000|C0205280|C0032042|G0000000
"We conducted a double-blind, placebo-controlled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected non–small-cell lung cancer (NSCLC) receiving selenium supplementation.","We conducted double-blind, placebo-controlled trial evaluate incidence primary tumors (SPTs) patients resected non–small-cell lung cancer (NSCLC) receiving selenium supplementation.",G0000000|C0004927|C0013072|C1706408|C0008976|C0220825|C0021149|C0205225|C0027651|G0000000|C0030705|C0015252|G0000000|C0024109|C0006826|C0007131|C1514756|C0036581|C0242297
"Bupropion sustained release tablets were taken by those randomized to the active medication group in the following manner: For days 1–3, 150 mg once a day and then 150 mg twice a day (mid morning and late afternoon) for the remainder of the study (days 4–21).","Bupropion sustained release tablets randomized active medication manner: For days 1–3, 150 day 150 day (mid morning late afternoon) remainder study (days 4–21).",C0085208|C0443318|C0030685|C0039225|C0034656|C0205177|C0013227|G0000000|G0000000|C0439228|G0000000|C1442061|C0332173|C1442061|C0332173|C0444598|C0332170|C0205087|C0439550|G0000000|C0557651|C0439228|G0000000
RIF (600 mg) was administered once per day in a 4-month regimen for a total of 120 doses that could be given over 6 months.,RIF (600 mg) administered day 4-month regimen total 120 doses 6 months.,C0035608|C1442061|C0026410|C1521801|C0332173|C0332177|C0040808|C0439175|C1442061|C0178602|G0000000|C0439231
The effect of an attachment‐oriented couple intervention for breast cancer patients and partners in the early treatment phase: A randomised controlled trial.,The attachment‐oriented couple intervention breast cancer patients partners treatment phase: A randomised controlled trial.,G0000000|G0000000|C0010222|C0886296|C0006141|C0006826|C0030705|C0682323|C0039798|C0205390|G0000000|G0000000|C2587213|C0008976
"For artemether/lumefantrine (AL), the dosing was 1 crushed tablet for participants weighing between 5 and 15 kg; two crushed tablets for participants weighing between 15 and 25 kg; three tablets for participants weighing between 25 and 35 kg; four tablets for participants weighing between whose weight was at least equal to 35 kg.","For artemether/lumefantrine (AL), dosing 1 crushed tablet participants weighing 5 15 kg; crushed tablets participants weighing 15 25 kg; tablets participants weighing 25 35 kg; tablets participants weighing weight equal 35 kg.",G0000000|C0936150|C0202311|G0000000|G0000000|C0185060|C0039225|C0679646|C1305866|G0000000|C0450371|C0022718|C0185060|C0039225|C0679646|C1305866|C0450371|C0450371|C0022718|C0039225|C0679646|C1305866|C0450371|C0450371|C0022718|C0039225|C0679646|C1305866|C0005910|C0205163|C0450371|C0022718
"During radiotherapy, patients in the verum group received 500 μg of Se (as inorganic sodium selenite; selenase®) per os on the days of RT and 300 μg of Se on the days without treatment until the last day of radiotherapy.","During radiotherapy, patients verum received 500 μg Se (as inorganic sodium selenite; selenase®) os days RT 300 μg Se days treatment day radiotherapy.",G0000000|C0034619|C0030705|G0000000|C1514756|C1442061|G0000000|C0036919|G0000000|C1881215|C0037473|C0036580|G0000000|C0229090|C0439228|C0230425|C1442061|G0000000|C0036919|C0439228|C0039798|C0332173|C0034619
"After providing informed consent, patients were randomly assigned in a ratio of two to one to either the carboplatin plus paclitaxel with bevacizumab (CPB) or carboplatin plus paclitaxel and placebo (CP) arm.","After providing informed consent, patients randomly assigned ratio carboplatin paclitaxel bevacizumab (CPB) carboplatin paclitaxel placebo (CP) arm.",G0000000|C1999230|C1522154|C1511481|C0030705|G0000000|C1516050|C0456603|C0079083|C0144576|C0796392|G0000000|C0079083|C0144576|C0032042|C4050020|C0446516
"The mDCF regimen was administered every 2 weeks, initially for a maximum of 12 cycles (24 weeks of treatment), docetaxel 40 mg/m2 (intravenous infusion over 60 min) on day 1, followed by leucovorin 400 mg/m2 (intravenous infusion over 120 min) on day 1, followed by 5-fluorouracil 400 mg/m2 (intravenous bolus) on day 1, and then 5-fluorouracil 1000 mg/m2/day continuous intravenous infusion on day 1 and day 2, followed by cisplatin 40 mg/m2 (intravenous infusion over 60 min) on day 3.","The mDCF regimen administered 2 weeks, initially maximum 12 cycles (24 weeks treatment), docetaxel 40 mg/m2 (intravenous infusion 60 min) day 1, leucovorin 400 mg/m2 (intravenous infusion 120 min) day 1, 5-fluorouracil 400 mg/m2 (intravenous bolus) day 1, 5-fluorouracil 1000 mg/m2/day continuous intravenous infusion day 1 day 2, cisplatin 40 mg/m2 (intravenous infusion 60 min) day 3.",G0000000|G0000000|C0040808|C1521801|G0000000|C0439230|C0205265|C0806909|C0450371|C1511572|C0450371|C0439230|C0039798|C0246415|C0450371|C0026410|C0348016|C0574032|C0450371|C0702093|C0332173|G0000000|C0023413|C1442061|C0026410|C0348016|C0574032|C1442061|C0702093|C0332173|G0000000|C0016360|C1442061|C0026410|C0348016|C1511237|C0332173|G0000000|C0016360|G0000000|C0439422|C0549178|C0348016|C0574032|C0332173|G0000000|C0332173|G0000000|C0008838|C0450371|C0026410|C0348016|C0574032|C0450371|C0702093|C0332173|G0000000
The study assessed the immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Korean women aged 15-25 years.,The study assessed immunogenicity safety human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine healthy Korean women aged 15-25 years.,G0000000|C0557651|C1516048|C4054739|C0036043|C0086418|C0030358|C0021344|C0001551|C0027530|C0006826|C0042210|C3898900|C1556095|C0043210|C0001779|C0450371|C0439234
Patients with CR were randomized to PUVA maintenance for 9 months (14 total exposures) or no maintenance.,Patients CR randomized PUVA maintenance 9 months (14 total exposures) maintenance.,C0030705|C0201975|C0034656|C0853073|C0024501|G0000000|C0439231|C0450371|C0439175|C0274281|C0024501
"Fifty percent of the patients were randomized to receive thalidomide (400 mg daily) during induction, after transplantation consolidation, and maintenance therapy.","Fifty percent patients randomized receive thalidomide (400 daily) induction, transplantation consolidation, maintenance therapy.",C3816723|C0439165|C0030705|C0034656|C1514756|C0039736|C1442061|C0332173|C0205263|C0040732|C0702116|C0024501|C0039798
This study was designed to compare clinical outcomes for laparoscopic distal pancreatectomy (LDP) and open distal pancreatectomy (ODP) performed at a single institution.,This study designed compare clinical outcomes laparoscopic distal pancreatectomy (LDP) distal pancreatectomy (ODP) performed single institution.,G0000000|C0557651|C1707689|C1707455|C0205210|C1274040|C0031150|C0205108|C0030279|C2985237|C0205108|C0030279|G0000000|C0884358|C0037179|C0018704
"The objective of this prospective randomized multicenter study was to compare the efficacy, safety, and tolerance of meropenem monotherapy with those of the combination of ceftazidime plus amikacin for the empirical treatment of fever in granulocytopenic cancer patients.","The objective prospective randomized multicenter study compare efficacy, safety, tolerance meropenem monotherapy combination ceftazidime amikacin empirical treatment fever granulocytopenic cancer patients.",G0000000|C0018017|C0023981|C0034656|C0439743|C0557651|C1707455|C1280519|C0036043|C0013220|C0066005|G0000000|C0205195|C0007559|C0002499|C1880496|C0039798|C0015967|C0001824|C0006826|C0030705
"The starting dose of pitavastatin in the 2-mg group was 1 mg, and was increased to 2 mg after Week 4.","The starting dose pitavastatin 2-mg 1 mg, increased 2 Week 4.",G0000000|C0439659|C0178602|C1101838|C0026410|G0000000|C0026410|C0205217|G0000000|C0332174|G0000000
Training of the paramedics involved a standardized national curriculum and clinical training period.,Training paramedics involved standardized national curriculum clinical training period.,C0040607|C0030450|C1314939|G0000000|C3245503|C0010478|C0205210|C0040607|C0439531
Patients enrolled in arm A subsequently received on day 1 of each 3-week cycle epirubicin 50 mg/m2 IV followed by cisplatin 60 mg/m2 IV over 60 minutes and fluorouracil 200 mg/m2 continuous IV infusion once per day for 21 days.,Patients enrolled arm A subsequently received day 1 3-week cycle epirubicin 50 mg/m2 IV cisplatin 60 mg/m2 IV 60 minutes fluorouracil 200 mg/m2 continuous IV infusion day 21 days.,C0030705|G0000000|C0446516|G0000000|G0000000|C1514756|C0332173|G0000000|C0332174|C1511572|C0014582|C0450371|C0026410|C0022326|C0008838|C0450371|C0026410|C0022326|C0450371|C0439232|C0016360|C1442061|C0026410|C0549178|C0022326|C0574032|C0332173|C0450371|C0439228
"Units were randomized to either perform daily bathing of patients with non-antimicrobial washcloths (control) [Comfort Bath, SAGE Products, Inc.] or washcloths impregnated with 2% CHG (intervention) [2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation, SAGE Products inc.] during the initial 6-month study period, followed by daily bathing with the alternate product for the second six-month period.","Units randomized perform daily bathing patients non-antimicrobial washcloths (control) [Comfort Bath, SAGE Products, Inc.] washcloths impregnated 2% CHG (intervention) [2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation, SAGE Products inc.] initial 6-month study period, daily bathing alternate product six-month period.",C0439148|C0034656|C0884358|C0332173|C0150141|C0030705|C1518422|C0879141|C0243148|C1331418|C0150141|C1122976|C1514468|G0000000|C0879141|G0000000|G0000000|C0008586|C0886296|G0000000|C0008196|C0017714|C0039717|C0030705|C0445204|C0444099|C1521827|C1122976|C1514468|G0000000|C0205265|C0332177|C0557651|C0439531|C0332173|C0150141|C0332270|C1514468|C0585339|C0439531
"Sodium thio-sulfate at a dose of 20 g per square meter was administered intravenously, over a period of 15 minutes, 6 hours after the end of the cisplatin infusion.","Sodium thio-sulfate dose 20 square meter administered intravenously, period 15 minutes, 6 hours cisplatin infusion.",C0037473|C1412102|C0178602|C0450371|C0205120|C0475209|C1521801|G0000000|C0439531|C0450371|C0439232|G0000000|C0439227|C0008838|C0574032
"During each 16-week period, patients received 250 µg of fluticasone (Flovent Diskus, GlaxoSmithKline) twice daily (inhaled-corticosteroid [ICS] step-up therapy), 100 µg of fluticasone plus 50 µg of the long-acting beta-agonist salmeterol (Advair Diskus, GlaxoSmithKline) twice daily (LABA step-up ther-apy), or 100 µg of fluticasone twice daily plus 5 or 10 mg of the leukotriene-receptor antagonist montelukast (Singulair, Merck) daily (LTRA step-up therapy).","During 16-week period, patients received 250 µg fluticasone (Flovent Diskus, GlaxoSmithKline) daily (inhaled-corticosteroid [ICS] step-up therapy), 100 µg fluticasone 50 µg long-acting beta-agonist salmeterol (Advair Diskus, GlaxoSmithKline) daily (LABA step-up ther-apy), 100 µg fluticasone daily 5 10 leukotriene-receptor antagonist montelukast (Singulair, Merck) daily (LTRA step-up therapy).",G0000000|C0450371|C0439531|C0030705|C1514756|C1442061|G0000000|C0082607|C0720466|C1553480|C1552903|C0332173|C0004048|C0022521|C0454366|C0039798|C1442061|G0000000|C0082607|C0450371|G0000000|C0205166|C0330390|C0073992|C0965130|C1553480|C1552903|C0332173|G0000000|C0454366|C3539705|C1442061|G0000000|C0082607|C0332173|G0000000|C0450371|C0206517|C0231491|C0298130|C0595724|G0000000|C0332173|C3537183|C0454366|C0039798
"Of the 255 patients, 236 was allocated to receive at least one cycle of CS (n = 120) or CF (n = 116).","Of 255 patients, 236 allocated receive cycle CS (n = 120) CF (n = 116).",G0000000|C1442061|C0030705|C1442061|G0000000|C1514756|C1511572|C0010182|C0369718|G0000000|C1442061|C0009738|C0369718|G0000000|C1442061
"All subjects received calcium 500 mg three times daily throughout the study, and were asked to apply sunscreen (Sun Protection Factor 65) between May and September.","All subjects received calcium 500 times daily study, apply sunscreen (Sun Protection Factor 65) May September.",G0000000|C0681850|C1514756|C0006675|C1442061|C0040223|C0332173|C0557651|C1632850|C0038818|C0038817|C1545588|C1521761|C0450371|G0000000|C3828193
"Methods: After three consecutive weekly visits, 86 patients were randomised to receive either fluticasone 500 µg twice daily (n = 43, 23F, mean (SD) age 57.7 (14.4) years) or matched placebo (n = 43, 34F, 59.2 (14.2) years) and reviewed regularly for 52 weeks in a double blind fashion.","Methods: After consecutive weekly visits, 86 patients randomised receive fluticasone 500 µg daily (n = 43, 23F, (SD) age 57.7 (14.4) years) matched placebo (n = 43, 34F, 59.2 (14.2) years) reviewed regularly 52 weeks double blind fashion.",C0025663|G0000000|C1707491|C0332174|C0545082|C0450371|C0030705|G0000000|C1514756|C0082607|C1442061|G0000000|C0332173|C0369718|G0000000|C0450371|G0000000|G0000000|C0001779|C0450371|C0450371|C0439234|C0150103|C0032042|C0369718|G0000000|C0450371|G0000000|C0450371|C0450371|C0439234|C0282443|G0000000|C0450371|C0439230|C0205173|C0150108|G0000000
"Between March 25, 2009, and July 12, 2010, 202 patients recruited from 14 sites were randomized to capecitabine–cisplatin plus either placebo (n = 102) or bevacizumab (n = 100; Fig.","Between March 25, 2009, July 12, 2010, 202 patients recruited 14 sites randomized capecitabine–cisplatin placebo (n = 102) bevacizumab (n = 100; Fig.",G0000000|C3829202|C0450371|G0000000|C3829447|C0450371|G0000000|C1442061|C0030705|G0000000|C0450371|C0205145|C0034656|G0000000|C0032042|C0369718|G0000000|C1442061|C0796392|C0369718|G0000000|C1442061|C0349966
METHODS—Seventy five infants less than 30 weeks of gestation and ventilated from birth for lung disease were randomly assigned to receive erythromycin intravenously for 7 days or to no treatment.,METHODS—Seventy infants 30 weeks gestation ventilated birth lung disease randomly assigned receive erythromycin intravenously 7 days treatment.,G0000000|C0021270|C0450371|C0439230|C0032961|C0231923|C0005615|C0024109|C0012634|G0000000|C1516050|C1514756|C0014806|G0000000|G0000000|C0439228|C0039798
Block randomization was used to assign participants to a 12-week Iyengar-based yoga intervention or to 12 weeks of health education (control).,Block randomization assign participants 12-week Iyengar-based yoga intervention 12 weeks health education (control).,C0028778|C0034656|C1516050|C0679646|C0450371|C1527178|C0043418|C0886296|C0450371|C0439230|C0018684|C0013621|C0243148
Chemotherapy-naïve patients with advanced oesophago-gastric cancer were randomised to receive either 3-weekly DI (docetaxel 60 mg m−2 plus irinotecan 250 mg m−2 (Day 1)) or 3-weekly DF (docetaxel 85 mg m−2 (Day 1) followed by 5-fluorouracil 750 mg m−2 per day as a continuous infusion (Days 1–5)).,Chemotherapy-naïve patients advanced oesophago-gastric cancer randomised receive 3-weekly DI (docetaxel 60 mg m−2 irinotecan 250 mg m−2 (Day 1)) 3-weekly DF (docetaxel 85 mg m−2 (Day 1) 5-fluorouracil 750 mg m−2 day continuous infusion (Days 1–5)).,G0000000|C0030705|C0205179|C1522619|C0006826|G0000000|C1514756|C0332174|C3538902|C0246415|G0000000|C0123931|G0000000|C0332173|G0000000|C0332174|G0000000|C0246415|G0000000|C0332173|G0000000|C0016360|G0000000|C0332173|C0549178|C0574032|C0439228|G0000000
"Intervention One year of fortified milk providing additional 7.8 mg zinc, 9.6 mg iron, 4.2 µg selenium, 0.27 mg copper, 156 µg vitamin A, 40.2 mg vitamin C, 7.5 mg vitamin E per day (three feeds).","Intervention One fortified milk providing additional 7.8 zinc, 9.6 iron, 4.2 µg selenium, 0.27 copper, 156 µg vitamin A, 40.2 vitamin C, 7.5 vitamin E day (three feeds).",C0886296|C0205447|G0000000|C0026131|C1999230|C1524062|G0000000|C0043481|G0000000|C0302583|G0000000|G0000000|C0036581|C0450371|C0009968|C1442061|G0000000|C0042890|G0000000|C0450371|C0042890|G0000000|G0000000|C0042890|G0000000|C0332173|C0205449|C1510670
"The subjects were randomized to oral daily treatment with either 800 mg of green tea extract (45% EGCG) or placebo (800 mg of brown rice) for 4 months, and UF volumes were measured at the end, also by transvaginal ultrasonography.","The subjects randomized oral daily treatment 800 green tea extract (45% EGCG) placebo (800 brown rice) 4 months, UF volumes measured end, transvaginal ultrasonography.",G0000000|C0681850|C0034656|C0442027|C0332173|C0039798|C1442061|C0332583|C0039400|C2828366|C0450371|C0059438|C0032042|C1442061|C0678579|C0035567|G0000000|C0439231|G0000000|C0449468|C0444706|C0444930|C0175672|C0041618
Standard antiemetic treatment with ondansetron was administered to all patients.,Standard antiemetic treatment ondansetron administered patients.,C1442989|C0003297|C0039798|C0061851|C1521801|C0030705
"In the IRI-S group, S-1 (80 mg/m2) was given orally for 21 days and irinotecan (80 mg/m2) was infused intravenously on days 1 and 15 every 5 weeks.","In IRI-S group, S-1 (80 mg/m2) orally 21 days irinotecan (80 mg/m2) infused intravenously days 1 15 5 weeks.",G0000000|C0022077|C0441833|G0000000|C0450371|C0026410|C0442027|C0450371|C0439228|C0123931|C0450371|C0026410|G0000000|G0000000|C0439228|G0000000|C0450371|G0000000|C0439230
Patients in the intervention group attended 86% of the prescribed exercise sessions.,Patients intervention attended 86% prescribed exercise sessions.,C0030705|C0886296|C1456498|C0450371|C0278329|C0015259|C1883016
"Cisplatin was administered intravenously at 75 mg m−2 on day 1, followed by oral TMZ at 200 mg m−2 per day for 5 days in the CTI arm or by intravenous DTIC at 800 mg m−2 on day 1 in the CDI arm.","Cisplatin administered intravenously 75 mg m−2 day 1, oral TMZ 200 mg m−2 day 5 days CTI arm intravenous DTIC 800 mg m−2 day 1 CDI arm.",C0008838|C1521801|G0000000|G0000000|C0332173|G0000000|C0442027|C0076080|G0000000|C0332173|G0000000|C0439228|C1516774|C0446516|C0348016|C0010927|G0000000|C0332173|G0000000|C0282601|C0446516
"INTERVENTIONS: 200,000 IU (infants) or 400,000 IU (1-4 year olds) of vitamin A in oil or similar capsules of placebo divided into two daily oral doses, in addition to the standard treatment.","INTERVENTIONS: 200,000 IU (infants) 400,000 IU (1-4 olds) vitamin A oil capsules placebo divided daily oral doses, addition standard treatment.",C0886296|C1442061|C0049272|C0021270|C1442061|C0049272|G0000000|C0580836|C0042890|G0000000|C0028908|C0006935|C0032042|C0332849|C0332173|C0442027|C0178602|C0332287|C1442989|C0039798
Infants requiring mechanical ventilation had been randomly allocated to receive either morphine (n=62) or other (n=33) solutions starting on the first day of life.,Infants requiring mechanical ventilation randomly allocated receive morphine (n=62) (n=33) solutions starting day life.,C0021270|G0000000|C0443254|C0035203|G0000000|G0000000|C1514756|C0026549|C0369718|C0369718|C0037633|C0439659|C0332173|C0376558
"The schools will be randomised, within region, to receive hand sanitisers and an education session on hand hygiene, or an education session on hand hygiene alone.","The schools randomised, region, receive hand sanitisers education session hand hygiene, education session hand hygiene alone.",G0000000|C0036375|G0000000|C0017446|C1514756|C0018563|G0000000|C0013621|C1883016|C0018563|C0020405|C0013621|C1883016|C0018563|C0020405|C0205171
"In this double-blind, phase 3 study, enrolled patients were randomly assigned in a 1:1:1 ratio to receive 3 mg of nivolumab per kilogram of body weight every 2 weeks (plus ipilimumab-matched placebo), or 1 mg of nivolumab per kilogram every 3 weeks plus 3 mg of ipilimumab per kilogram every 3 weeks for 4 doses (plus nivolumab-matched placebo), followed by 3 mg of nivolumab per kilogram every 2 weeks for cycle 3 and beyond, or 3 mg of ipilimumab per kilogram every 3 weeks for 4 doses (plus nivolumab-matched placebo).","In double-blind, phase 3 study, enrolled patients randomly assigned 1:1:1 ratio receive 3 nivolumab kilogram body weight 2 weeks (plus ipilimumab-matched placebo), 1 nivolumab kilogram 3 weeks 3 ipilimumab kilogram 3 weeks 4 doses (plus nivolumab-matched placebo), 3 nivolumab kilogram 2 weeks cycle 3 beyond, 3 ipilimumab kilogram 3 weeks 4 doses (plus nivolumab-matched placebo).",G0000000|C0013072|C0205390|G0000000|C0557651|G0000000|C0030705|G0000000|C1516050|G0000000|C0456603|C1514756|G0000000|C3657270|C0439209|C0242821|C0005910|G0000000|C0439230|C0332287|C1367202|C0032042|G0000000|C3657270|C0439209|G0000000|C0439230|G0000000|C1367202|C0439209|G0000000|C0439230|G0000000|C0178602|C0332287|C3657270|C0032042|G0000000|C3657270|C0439209|G0000000|C0439230|C1511572|G0000000|G0000000|G0000000|C1367202|C0439209|G0000000|C0439230|G0000000|C0178602|C0332287|C3657270|C0032042
"This phase 2 trial enrolled a total of 116 patients: 39 patients were randomly assigned to receive high-dose bevacizumab (10 mg/kg), 37 patients to low-dose bevacizumab (3 mg/kg), and 40 patients to placebo.","This phase 2 trial enrolled total 116 patients: 39 patients randomly assigned receive high-dose bevacizumab (10 mg/kg), 37 patients low-dose bevacizumab (3 mg/kg), 40 patients placebo.",G0000000|C0205390|G0000000|C0008976|G0000000|C0439175|C1442061|C0030705|C0450371|C0030705|G0000000|C1516050|C1514756|C0444956|C0796392|C0450371|C0439272|C0450371|C0030705|C0445550|C0796392|G0000000|C0439272|C0450371|C0030705|C0032042
"After signing informed consent, patients were randomized to placebo or ZA 4 mg iv over 15 min every 3 months for 12 months.","After signing informed consent, patients randomized placebo ZA 4 iv 15 min 3 months 12 months.",G0000000|C0311392|C1522154|C1511481|C0030705|C0034656|C0032042|C0037712|G0000000|C0022326|C0450371|C0702093|G0000000|C0439231|C0450371|C0439231
"At this point of the operation, the patients were randomly assigned for either a colonic pouch or a side-to-end anastomosis.","At operation, patients randomly assigned colonic pouch side-to-end anastomosis.",G0000000|C0543467|C0030705|G0000000|C1516050|C0009368|C0222017|C0441987|C0332853
"IFN-α-2b (Intron; Schering, Kenilworth, NJ) was provided by the Cancer Therapy Evaluation Program and administered identically in both arms (subcutaneously at a starting dose of 9 MU on 3 nonconsecutive days per week with dose reduction to 6 MU and 3 MU permitted for IFN-related toxicity).","IFN-α-2b (Intron; Schering, Kenilworth, NJ) provided Cancer Therapy Evaluation Program administered identically arms (subcutaneously starting dose 9 MU 3 nonconsecutive days week dose reduction 6 MU 3 MU permitted IFN-related toxicity).",G0000000|C0021920|G0000000|G0000000|C0027971|C1999230|C0006826|C0039798|C0220825|C1709697|C1521801|G0000000|C0206655|G0000000|C0439659|C0178602|G0000000|C0028971|G0000000|G0000000|C0439228|C0332174|C0178602|C0301630|G0000000|C0028971|G0000000|C0028971|C0329040|C0439849|C0040539
METHODS—Twenty four patients with CF were randomised to receive β-carotene 1 mg/kg/day (maximum 50 mg/day) for three months (high dose supplementation) and 10 mg/day for a further three months (low dose supplementation) or placebo.,METHODS—Twenty patients CF randomised receive β-carotene 1 mg/kg/day (maximum 50 mg/day) months (high dose supplementation) 10 mg/day months (low dose supplementation) placebo.,G0000000|C0030705|C0009738|G0000000|C1514756|G0000000|G0000000|C3665414|C0806909|C0450371|C0439422|C0439231|C0205250|C0178602|C0242297|C0450371|C0439422|C0439231|C0205251|C0178602|C0242297|C0032042
The comparison group received conventional physical exercise intervention (PEI) which consists of a 60-minute physical exercise session per week over a period of 12 weeks at the intervention center “Gesund.,The comparison received conventional physical exercise intervention (PEI) consists 60-minute physical exercise session week period 12 weeks intervention center “Gesund.,G0000000|C1707455|C1514756|C0439858|C0031809|C0015259|C0886296|C0814202|C0332529|C0450371|C0031809|C0015259|C1883016|C0332174|C0439531|C0450371|C0439230|C0886296|C0205099|G0000000
"All GBS patients were recruited from a double-blind, randomized placebo-controlled, multicentre study comparing IVIg + methylprednisolone (500 mg for five days) versus IVIg + placebo [18].","All GBS patients recruited double-blind, randomized placebo-controlled, multicentre study comparing IVIg + methylprednisolone (500 days) versus IVIg + placebo [18].",G0000000|C0018378|C0030705|G0000000|C0013072|C0034656|C1706408|C0439743|C0557651|C1707455|C0085297|G0000000|C0025815|C1442061|C0439228|G0000000|C0085297|G0000000|C0032042|C0450371
"We randomized 4,372 patients with stable coronary heart disease to clarithromycin 500 mg (n = 2,172) or placebo (n = 2,200) once daily for 2 weeks.","We randomized 4,372 patients stable coronary heart disease clarithromycin 500 (n = 2,172) placebo (n = 2,200) daily 2 weeks.",G0000000|C0034656|C1442061|C0030705|C0205360|C0018787|C0018787|C0012634|C0055856|C1442061|C0369718|G0000000|C1442061|C0032042|C0369718|G0000000|C1442061|C0332173|G0000000|C0439230
"Girls were randomized 1:1 and received 2 vaccine doses either 6 months (2D_M0,6) or 12 months apart (2D_M0,12); women received 3 doses at months 0, 1, and 6 (3D_M0,1,6).","Girls randomized 1:1 received 2 vaccine doses 6 months (2D_M0,6) 12 months (2D_M0,12); women received 3 doses months 0, 1, 6 (3D_M0,1,6).",C0870604|C0034656|G0000000|C1514756|G0000000|C0042210|C0178602|G0000000|C0439231|C0043316|C0450371|C0439231|C0043316|C0043210|C1514756|G0000000|C0178602|C0439231|G0000000|G0000000|G0000000|C0043316
The web-based collaborative care intervention included access to a psycho-educational website (see Figure 2) and to a collaborative care coordinator with training and experience with cognitive-behavioral therapy (CBT) and psycho-oncology.,The web-based collaborative care intervention included access psycho-educational website (see Figure 2) collaborative care coordinator training experience cognitive-behavioral therapy (CBT) psycho-oncology.,G0000000|C0282111|C0282116|C1947933|C0886296|C0332257|C0444454|C0871175|C2349146|C0042789|G0000000|G0000000|C0282116|C1947933|C1711307|C0040607|C0237607|C1516691|C0039798|C0009244|C0027651
"The intervention includes: (1) implementation of a primary care electronic CKD registry that notifies practice teams of patients’ CKD status and employs a patient profile and quarterly feedback to encourage provision of guideline-concordant care at point-of-care and via outreach; and (2) a language-concordant, culturally-sensitive self-management support program that consists of automated telephone modules, provision of low-literacy written patient-educational materials and telephone health coaching.","The intervention includes: (1) implementation primary care electronic CKD registry notifies practice teams patients’ CKD status employs patient profile quarterly feedback encourage provision guideline-concordant care point-of-care outreach; (2) language-concordant, culturally-sensitive self-management support program consists automated telephone modules, provision low-literacy written patient-educational materials telephone health coaching.",G0000000|C0886296|C0332257|G0000000|C1708476|C0205225|C1947933|C0013850|C1561643|C0034975|C0422202|C0237607|C0871489|G0000000|C1561643|C0449438|C0457083|C0030705|C1979963|C0332179|C0015744|G0000000|C1549071|C0162791|C1947933|C0282664|C0683805|G0000000|C0023008|C0010453|C0086969|C0183683|C1709697|C0332529|C0205554|C0039457|C1709061|C1549071|C0205251|C0043266|C0030688|C0520510|C0039457|C0018684|C0557773
"Among the eligible patients, 11.5% and 4.6% of patients on the AT and AC arms, respectively, received lower than 90% of the planned cumulative dose.","Among eligible patients, 11.5% 4.6% patients AT AC arms, respectively, received lower 90% planned cumulative dose.",G0000000|C1548635|C0030705|C0450371|G0000000|C0030705|G0000000|C0003354|C0206655|G0000000|C1514756|C0441994|C0450371|C1301732|C1511559|C0178602
"They will participate either in the Onco-Move or the OnTrack program, or will undergo usual care.","They participate Onco-Move OnTrack program, undergo usual care.",G0000000|G0000000|C0560560|G0000000|C1709697|G0000000|C3538928|C1947933
